This page contains a Flash digital edition of a book.
SUSTAINABLE AFFORDABLE HEALTHCARE


Figure three: Prevalence of osteoarthritis of the knee by age/sex/region


WHO osteoarthritis report. A - regions = Developed countries in North America/Western Europe/Japan/Australia/ New Zealand; AF = Sub-Saharan Africa; AM BD = Developing countries in the Americas; EM = Eastern Mediterra- nean/North Africa; EU BC = Developing countries in Europe; SEA = South-East Asia; WP B = Countries in Western Pacific region.


This is due to an increasing


sedentary lifestyle, reduction in physical activity, changes in food processing, urbanization and changes to transportation. A recent study published in the leading medical journal The Lancet in 2012 reports that obesity has now become the sixth most important risk factor for death. An ageing population is a significant risk factor for


musculoskeletal disease. Females live longer than males with the worldwide life expectancy of a female born in 2050 predicted to be 79 years versus 74 years for a male. In the U.K., life expectancy for females is 83 and 79 for males, an increase from 53 and 49 years over the past 100 years. Overall, approximately 14 per cent of people (18 per cent female and 10 per cent male) will suffer from symptomatic osteoarthritis worldwide. The knee


44 | The Parliamentarian | 2013: Issue One


is affected more than the hip, and Europe and America have the highest prevalence compared to the rest of the world. The economic burden of musculoskeletal disease worldwide is increasing. A study in 1997 of Australia, Canada, France, the U.K. and the U.S.A. found that the cost was 2.5 per cent of Gross National Product. If this figure is used with today’s world Gross National Income


of 2.5 per cent, the cost is equivalent to £1.28 trillion (using 2011 figures). As the U.K.’s and the world’s


populations are ageing, it is clear that the burden of musculoskeletal disease could severely damage the economy and, if we do not change, treatment costs may become unsustainable.


Focused action – A new model The NHS is on a knife-edge with


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92